New Blood Sugar Meter Rewards Children with Diabetes for Testing Regularly

August 2nd, 2011

Diabetes is one of the most common chronic diseases in children, and the incidence of juvenile diabetes is growing. According to the American Diabetes Association, about 215,000 children and youth have diabetes. Most of them are type 1 diabetics, but more children are being diagnosed with type 2. This increase in type 2 diabetes in children is being attributed to poor diet, not enough physical activity, and resulting weight gain.

A new blood sugar meter designed for kids can actually make glucose testing fun. The Bayer Didget Meter has a five second testing time, a large easy to read screen, and a selectable post meal reminder to prompt children to test their blood sugar levels after eating.

Perhaps its best element is the feature that it adds a fun factor for children who glucose test regularly by rewarding them with free Nintendo DS games. To see a picture of and read more about the Bayer Didget Meter on diabetic live, >CLICK HERE.<

Helping Friends to Understand Diabetes

August 4th, 2011

explaining insulin dependent diabetes Diabetes Guide Gary Gilles has written an excellent post titled Helping Friends to Understand Diabetes - Answers to 9 Common Questions. The post is aimed at insulin dependent type 1 diabetics, and tackles common myths and questions about blood glucose testing, insulin injections, diabetes and diet, and episodes of low blood sugar.

The post begins with:

Educating friends about your type 1 diabetes can be challenging. Many myths still exist about diabetes and you can do yourself a big favor by trying to replace those myths with accurate information. Here are nine of the most common questions your friends might be thinking and how to answer them.

To read the 9 common questions and Gilles helpful suggested answers on, >CLICK HERE.<

Researcher Links Diabetic Complication to Nerve Damage in Bone Marrow

August 5th, 2011

?ScienceDaily (2010-01-08) -- Scientists have discovered a link between diabetes and bone marrow nerve damage that may help treat one of the most common and potentially blindness-causing diabetes complications - diabetic retinopathy.

The key to better treating retinopathy - damage to blood vessels in the retina that affects up to 80 percent of diabetic patients - lies not in the retina but in damage to the nerves found in bone marrow that leads to the abnormal release of stem cells, said Julia Busik, an associate professor in MSU's Department of Physiology.

> read full article

Arthritis Drug a Future Diabetes Medication?

August 9th, 2011

A collaborative group of researchers including the American Diabetes Association and the Juvenile Diabetes Research Foundation has been testing the medication abatacept (CTLA4 immunoglobin fusion protein) as a possible treatment for type 1 diabetes. Abatacept, better known by its brand name Orencia, is FDA approved to treat autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

Type 1 diabetes is an autoimmune disease in which T-cells in the body's immune system mistakenly attack the insulin producing beta cells in the pancreas. With the pancreas producing little or no insulin, type 1 diabetics must rely on insulin injections to regulate their blood sugar levels. Those type 1 diabetes who continue to produce some insulin have an easier time keeping their blood sugar in the normal range, and have less risk of diabetes complications.

Abatacept blocks the activation of the immune system's aggressive and destructive T-cells. The researchers hoped the medication would protect the remaining beta cells in the pancreas from being destroyed, allowing them to continue to make at least a little of their own insulin.

Researchers recruited 112 newly diagnosed type 1 diabetics aged 6 to 45, all of whom still had some functioning beta cells. Two thirds of the participants were given abatacept intravenously over two years, and one third was given a placebo. The two-year study ended recently, although participants will be followed up for another two years. Initial results are encouraging, with the participants who received the abatacept showing 59% more insulin production than the control group.

"I have spent my career on the quest to find a treatment and cure for type 1 diabetes, and thus it was very gratifying when we unblinded the clinical results and discovered that abatacept had benefit," said principle investigator Dr. Tihamer Orban. "From my experience though," he cautioned, "abatacept is not likely to be the complete answer, and type 1 diabetes patients will likely benefit from cocktail combinations with other drugs. This synergistic approach has a great future."

Orban's is the CEO of the clinical stage biotechnology company, Orban Biotech. Orban Biotech has launched a pre-clinical study evaluating the combination of abatacept with the company's antigen-based therapy insulin B chain vaccine. The vaccine, which is entering into a Phase II trial, is designed to arrest the autoimmune response and re-establish tolerance towards insulin, preserving the body's own insulin production.

This study is one of several which show promise of novel ways to improve diabetes control, and perhaps free insulin dependent diabetics from the need for frequent insulin injections and other diabetes medication.

Swamp Gas Plays a Role in Diabetes Control

August 9th, 2011

The last decade has been an exciting time in diabetes research, with scientists approaching diabetes control from many different angles. Enter hydrogen sulfide, the foul smelling gas better known as "swamp gas". It turns out the sewer-scented compound, a substance that occurs naturally in our bodies, may play an important role in protecting blood vessels from diabetic complications.

In a finding that they say "may open the door for new therapies", researchers discovered that providing cells with high levels of hydrogen sulfide protected them against the toxic effects of sugar.

To read the full story on, a news publication focused on the latest research in diabetes drugs, diets, and medical advances, >CLICK HERE.<

New Protein May Help Treat Diabetes and Obesity

August 10th, 2011

ScienceDaily (2011-08-09) -- A newly-identified protein may hold the key to keeping appetite and blood sugar in check, according to a new study. Researchers found that rats administered with nesfatin-1 ate less, used more stored fat and became more active. In addition, the protein stimulated insulin secretion from the pancreatic beta cells of both rats and mice.

"[The rats] actually ate more frequently but in lesser amounts," says Unniappan, a member of York's neuroscience graduate diploma program, and a recipient of a Canadian Institutes of Health Research (CIHR) New Investigator Award. "In addition, they were more active and we found that their fatty acid oxidization was increased. In other words, the energy reserve being preferably used during nesfatin-1 treatment was fat. This suggests more fat loss, which could eventually result in body weight loss," he says. read full article...

Diabetics May Be Wasting Billions on Unnecessary Medication

August 11th, 2011

Type 2 diabetes patients may be wasting billions of dollars on unnecessary medication. Three doctors who recently evaluated the effectiveness of commonly prescribed fibrates in diabetes patients with high cholesterol have said that the drugs have not been proven effective. The doctors, who conducted the research for the FDA, reported their findings in a commentary in the New England Journal of Medicine.

Diabetics are at high risk of cardiovascular disease, and fibrates are commonly prescribed along with statins and diabetes medication to lower the risk of heart attacks. The statins and fibrates were thought to work in combination to lower "bad" LDL cholesterol and raise "good" HDL cholesterol levels.

But, although fibrates such as Tricor (fenofibrate), Lopid (gemfibrozil) and Trilipix (fenofibric acid) are routinely prescribed to diabetics, there have been few studies assessing their effectiveness. "Thousands and thousands of Americans take fibrates every day," said one of the commentary's authors, Dr Sanjay Kaul from the Cedars-Sanai Heart Institute, "But so far there are no long-term studies showing that fibrates lower cardiovascular risk or improve survival among diabetes patients who are also on statins."

The commentary authors are calling for more studies, and recommending doctors only prescribe fibrates along with statins to diabetics at high risk of heart attack, and only after they have achieved healthy LDL levels.

While no diabetic should adjust their diabetes medication without consulting their physician, many type 2 diabetics may be able to lower the cost of their diabetes medicine without affecting their diabetes control based on this new recommendation.

Mealtime Insulin Injections May be Replaced by an Insulin Inhaler

August 12th, 2011

There's good news for insulin dependent diabetics who rely on fast-acting mealtime insulin injections to keep their blood sugar under control. MannKind Corporation has the go-ahead to continue clinical testing of its investigational inhaled insulin, AFREZZA. The drug maker and the FDA met to confirm the protocols for two new studies, one in type 1 diabetics, and one in type 2 diabetics.

AFREZZA is an ultra-rapid acting inhaled insulin which uses patented technology to deliver powdered insulin from a thumb-sized device into the lungs. The lungs are an effective option for delivering diabetes medication, largely because of their huge surface area (about the size of a tennis court).MannKind focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Now in late stage clinical investigation, AFREEZA is its lead product candidate. Shares of the company jumped 20% at the news that the design of the follow-up clinical trials had been confirmed.

MannKind has been seeking approval for its new generation diabetes medication since March of 2009, but was asked twice to run additional clinical trials in order to provide the FDA with more information. One of the approval delays was due to the drug maker updating the design of its insulin inhaler after applying for approval of the earlier design. The FDA was concerned that there was not enough data to support a switch to the new generation device, and asked that both models be tested together.

Clinical trials of the initial design of the insulin inhaler were promising. Participants reported being pleased with the innovative insulin delivery device, and experienced less hypoglycemia and weight gain than did controls using a standard combination of long-acting insulin glargine and twice a day 70 30 insulin injections.

Insulin can't be taken orally, as digestive juices break it down before it can be used by the body. Currently, the only means of delivering insulin are subcutaneous insulin injections or intravenously. Because AFREEZA is a short-acting mealtime insulin, type 1 diabetics will need to combine it with long-acting insulin injections for complete diabetes control.

Dr. Larry Deeb, a pediatric endocrinologist from the University of Florida College of Medicine, says that failure to comply with regular insulin dosing is one of the major issues in diabetes, often because of the discomfort and inconvenience of insulin injections. Deeb says that finding an alternative insulin delivery method is crucial, especially for children and the needle-phobic.

Should it be approved, AFREEZA would be the second inhaled insulin to hit the market. Pfizer received approval to market a similar product, Exubera, several years ago, but, surprisingly, the product never caught on with diabetics, and was withdrawn from the market a year later.

AFREZZA is easier to use, faster acting and boasts better bioavailability than Exubera, enabling diabetics to achieve more satisfactory insulin levels using smaller amounts. Despite Exubera's unexpected failure, AFREEZA is expected to be a blockbuster diabetes drug when it becomes available.

Eating Red and Processed Meats Increases Risk of Diabetes

August 15th, 2011

A study published in the American Journal of Clinical Nutrition found that the more red meat people eat, especially processed meat, the higher their risk of developing type 2 diabetes.

Processed meats include the American staples bacon, sausage, hot dogs and most packaged sandwich meats. The study did not establish why red and processed meats increased the risk of developing diabetes. One theory is that the high amount of nitrates used as preservatives in processed meats may increase insulin resistance.

Others theorize that the large amount of iron in red meat leads to high iron stores in the body, which have been associated with an increased risk of type 2 diabetes. A third theory is that high meat consumption may contribute to obesity - a major risk factor for diabetes. The answer may lie in a combination of these factors.

To read more about the issue on WebMD, >CLICK HERE.<

New Class of Injectable Diabetes Medication for Type 2 Diabetics

August 16th, 2011

Liraglutide, marketed as Victoza, is a new approach to blood sugar control in type 2 diabetes. Although it is an injectable diabetes medication, it is not insulin, does not contain insulin, and is not taken with insulin. Victoza is not used to treat insulin dependent type 1 diabetes (although there has been a successful clinical trial using the diabetes drug along with insulin injections).

In type 2 diabetes, by far the most common form of the disease, the body either doesn't make enough insulin, or can not properly respond to the insulin it does make. Insulin is produced by beta cells in the pancreas. As type 2 diabetes progresses, beta cells stop working and die off, and even less insulin is produced. Victoza helps the beta cells in the pancreas make and release insulin.

Liraglutide belongs to a new class of diabetes drugs called incretin mimetics GLP-1 analogues. GLP-1 is a naturally occurring hormone that signals the pancreas to release insulin in response to high blood sugar levels. The hormone also prevents the liver from releasing too much sugar, and slows gastric emptying to avoid blood sugar spikes.

Liraglutide is almost identical (97%) to the GLP-1 hormone. Like GLP-1, Victoza makes more insulin available in your blood, and helps to lower your blood sugar levels. It is taken once a day as an injection, alone or in combination with another diabetes medication such as metformin.

Victoza is injected using a dial-a-dose injection pen, much like the long acting insulin Lantus SoloSTAR. The pen uses extremely short, thin (30 or 32 gauge) disposable needles. Victoza is injected into the fat under the skin with the push of a button on the top of the pen. After injection, it is slowly dispersed into the body. It can be taken with or without food and, unlike insulin injections, the dose does not need to be adjusted based on food intake or activity levels.

The FDA approved Victoza in early 2010, with a black box warning that it should only be prescribed to patients in which the potential benefits outweigh the potential risks. The black box warning stems largely from animal studies in which high doses of liraglutide appeared associated with thyroid tumors (including cancer) in mice. The FDA has ordered Victoza's manufacturer, Novo Nordisk, to conduct ongoing testing and monitoring, including a 15-year cancer registry.

Liraglutide is not recommended as a first-line diabetes medication. As with all diabetes drugs, Victoza should be used in combination with diet and exercise. Victoza can not be taken by people with certain medical conditions, including gastroparesis (delayed stomach emptying) and has not been tested in children. The most common Victoza side effects are nausea, headache and diarrhea.

Novo Nordisk has focused a great deal of its marketing campaign on the fact that most type 2 diabetics taking liraglutide lose weight. Marketing of the diabetes drug got off to a rocky start in Britain, when Novo Nordisk breached the Association of the British Pharmaceutical Industry's code of contact by promoting it before it was approved, and not providing information about Victoza side effects.

Exenatide (marketed as prescription Byetta) is another diabetes medication in the new class of incretin mimetics. Byetta, which requires twice a day injections, has similar actions to Victoza. It is not a GLP-1 analogue, but mimics the action of incretin (gastrointestinal) hormones, including GLP-1, to lower blood sugar. Both drugs arrived on the market in the same time frame, sparking a Byetta vs Victoza debate that is still ongoing.

Diabetes Videos on WebMD

August 18th, 2011

More and more people are turning to the web for information on health issues, including diabetes. WebMD is one of the most highly respected sources of timely and trusted medical news and information on the web. The site's Health A to Z section includes a comprehensive Diabetes Health Centre sub-section.

Aware that many people prefer to get their information in other ways rather than reading, WebMD has incorporated a number of alternative means of delivering information into their site, including interactive quizzes, tools such as a Food & Fitness Planner, and short documentary-style videos.

The diabetes-related videos feature real people in real life settings - diabetes patients, parents of diabetic children, researchers, and health care professionals. Currently, the site contains sixty diabetes videos on diverse topics, including:

  • Basic diabetes information (type 1 diabetes, type 2 diabetes, pre-diabetes, diabetes diagnosis, diabetes control, diabetes medication-)

  • Diabetes management (diet, foot care, glucose monitoring, A1C testing, hypoglycemia and hyperglycemia-)

  • Diabetes in children (preschool, young children, adolescents-)

  • Insulin delivery methods (insulin pumps, insulin inhalers, islet cells transplant-)

  • Diabetes research and studies (diabetes vaccine, stem cells, investigational diabetes medications, glucose monitoring tattoo, cord blood study-)

  • New diabetes treatments (islet cells transplant, continuous glucose monitors, botox for foot wounds, silicone eye oil for retinopathy-)

  • Alternative diabetes treatment (vinegar for diabetes, antioxidants, hyperbaric oxygen, medicinal properties of kudzu-)

  • Diabetes complications (foot ulcers, diabetic retinopathy, diabetic neuropathy, diabetes and depression, kidney disease-)

Should a topic be of particular interest, every video is surrounded by links to related in-depth information. To view a WebMD Diabetes Health Centre video on a study on the use of vinegar as a diabetes medication >CLICK HERE.<

Security Flaws in Insulin Pump Technology

August 19th, 2011

A security researcher who is diabetic has identified flaws that could allow an attacker to remotely control insulin pumps and alter the readouts of blood-sugar monitors. As a result, diabetics could get too much or too little insulin, a hormone they need for proper metabolism.

Jay Radcliffe, an insulin dependent diabetic who experimented on his own equipment, shared his findings with The Associated Press before releasing them Thursday at the Black Hat computer security conference in Las Vegas.

The full article is published on the News Tribune.

Diabetes Drug Metformin Combined with Exercise Has Surprise Effect on Glucose Control

August 22nd, 2011

It's common enough for researchers to look at the impacts of prescribed drugs on the body. And if you're a diabetes researcher who believes that exercise has great benefits for those with type 2 diabetes, you're hoping your research will show that. But when Normand Boulé looked at the dual impacts of exercise and metformin - two of the most commonly-prescribed modalities for glucose control -the hoped-for double whammy wasn't the result.

Researchers looking at the effects of the oral diabetes medication metformin and exercise in Type 2 diabetes patients found that a combination of these modalities didn't lower glucose control as much as hoped. Surprisingly, study participants showed better glucose control when sedentary. Researchers think that because prescription metformin and exercise both act to lower glucose levels, the combination may have triggered a counter regulatory response by the body to prevent glucose levels dipping too much.

Read the full article on ScienceDaily-

New Treatment Approach for Diabetic Macular Edema

August 23rd, 2011

SOUTHAMPTON, England, August 23, 2011 /PRNewswire

KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need. KalVista's advanced pre-clinical product pipeline is targeting both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.

KalVista's scientific founders include world-leading experts in ophthalmology, diabetes and diabetes-related complications, Dr Lloyd Paul Aiello and Dr Edward P. Feener. Dr Aiello is Professor of Ophthalmology at Harvard Medical School, Director of the Joslin's Beetham Eye Institute and Inaugural Chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network.

Dr Feener is Associate Professor of Medicine at Harvard Medical School and an Investigator in Vascular Cell Biology at the Joslin Diabetes Center, where his team led the discovery of plasma kallikrein in the vitreous fluid from people with DME and has shown that inhibition of plasma kallikrein decreases pathological retinal vascular permeability in pre-clinical studies. Dr Aiello has guided the clinical development programs for a wide range of recent ophthalmology drugs, and has been a lead investigator in the trials determining the benefit of VEGF (vascular endothelial growth factor) inhibitors for the treatment of DME.

Plasma kallikrein is a circulating serine protease that represents an attractive drug target as it is believed to be central to the pathogenesis of DME within the diseased retina, but is not essential for normal function. The detrimental effects of plasma kallikrein on the retina occur independently of VEGF, which has been an area of intense recent interest as a target for treating DME.

However, while intravitreal VEGF inhibitors have shown clear benefit in clinical trials through reducing macular edema and increasing visual acuity, a large proportion of DME patients do not respond fully to VEGF treatment. KalVista's approach targeting plasma kallikrein inhibition therefore has the potential to add to the treatment options for sufferers of DME including those that are non-responsive to VEGF inhibitors.

KalVista is supporting the therapeutic expertise with a management team with proven experience in bringing small molecules from discovery through the clinic to commercialisation. This team is led by Andrew Crockett as CEO and includes the former discovery group from Vantia Therapeutics. This group developed the extensive library of proprietary plasma kallikrein inhibitors, including the lead compounds that now form the basis of KalVista's discovery platform.

The KalVista board of directors will include Graham Boulnois of SV Life Sciences as Chairman, Martin Edwards of Novo A/S as Non-executive Director and Andrew Crockett as CEO.

Dr Lloyd Paul Aiello, Director of Joslin's Beetham Eye Institute and Co-founder of KalVista, commented on today's announcement: "Diabetic macular edema remains one of the major challenges in ophthalmology, and is a leading cause of visual loss in the developed world. While new advances such as VEGF inhibitors are a breakthrough in treatment, current evidence demonstrates that a substantial number of patients with DME do not respond fully. I believe KalVista's approach, targeting a novel non-VEGF pathway, could represent a further important step in treating this condition."

Graham Boulnois of SV Life Sciences and Chairman of KalVista's board of directors, said: "The exciting discoveries regarding plasma kallikrein inhibition and its potential as a new approach to treating DME have created a significant opportunity. We believe that in KalVista we have put in place all the necessary scientific, clinical and drug discovery and development expertise, and sufficient funding, to capitalize on this opportunity and create a highly differentiated and valuable company."

Andrew Crockett, KalVista's CEO, said: "I am delighted that KalVista has garnered substantial financial support from leading life sciences investors Novo A/S and SV Life Sciences to fund this exciting new business. We have an ambitious target to become a leading company focused on the development of novel treatments for DME and believe we have the team, the expertise, the assets and the approach to achieve this goal."

KalVista is a new ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.

KalVista's founders include world-leading experts in diabetic retinopathy, Dr Lloyd Paul Aiello, Professor of Ophthalmology at Harvard Medical School and Director of the Joslin's Beetham Eye Institute, and Dr Edward Feener, Associate Professor of Medicine at Harvard Medical School and Joslin Diabetes Center. In addition to this therapeutic expertise, KalVista has a management team with proven experience in bringing small molecules through the clinic to commercialisation and as a result has attracted significant financial backing from leading life science investors, SV Life Sciences and Novo Ventures.

What is Stiff-Person Syndrome?

August 26th, 2011

One very rare and unusual condition associated with diabetes is Stiff-Person syndrome, also referred to as Myotonic Dystrophy. Stiff-Person syndrome (SPS) is a central nervous system disorder characterized by severe muscle stiffness that moves from place to place in the trunk, arms and legs. SPS affects about 1 in 1 million Americans, and about 1 in 10,000 diabetics.

Someone with SPS is exceedingly hypersensitive to normal stimuli such as sound, touch and emotional stress. A sudden noise, tap or worry can trigger muscle spasms that distort the body into hunched over stiff postures. People with SPS suffer from frequent falls when spasms are triggered by commonplace noises like a door slamming or a car horn. Because people with SPS lack normal protective reflexes, spasms and falls can result in serious injuries, including fractures, muscle tears and joint dislocations.

SPS is also referred to as "Stiff Man Syndrome", although - like many autoimmune conditions - it is much more common in women than in men. SPS usually strikes between the ages of 30 and 50, but the syndrome can also occur as Stiff Baby Syndrome in children under three. Commonly, SPS begins with an exaggerated upright posture due to muscle stiffness in the lower back, and then moves into the legs. As the disease progresses the patient must move very slowly, as rapid movements can trigger severe spasms.

The unusual and unfortunate symptoms of SPS can be confused with those of fibromyalgia, Parkinson's disease or multiple sclerosis. Sufferers may also be misdiagnosed as having an anxiety or psychosomatic disorder. A diagnosis of SPS is aided by the detection of elevated levels of the antibody glutamic acid decarboxylase (GAD), which is present in the cerebral spinal fluid of about 80% of SPS cases.

GAD antibodies tests are also an important diagnosis tool for diabetes mellitus. GAD tests are used to differentiate between types of diabetes, to predict the risk and track the progression of the disease, and to predict the need for insulin therapy in type 2 diabetics. GAD reduces the brain's main inhibitory transmitter, GABA. It's theorized that this reduction of GABA interferes with the modulation of spinal cord reflexes, resulting in the hyperactivity and hyperexcitabity that characterizes SPS.

SPS can be treated, but not cured. Symptoms can be eased with a combination of anti-anxiety medications, anti-convulsants, muscle relaxers and pain medication. A recent study proved intravenous immunoglobulin treatment (a therapy for autoimmune diseases and immune deficiencies) effective in reducing stiffness and hypersensitivity in patients with Stiff-Person syndrome. Another study using the arthritis drug rituximab led to disappointing results.

The cause of SPS remains a mystery, but it appears to be an out of kilter autoimmune response in the brain and spinal cord. SPS is associated with other autoimmune diseases such as diabetes, pernicious anemia, thyroiditis, and the skin disease vitiligo. The National Institute of Neurological Disorders and Stroke is continuing to both conduct and support research into SPS, focusing on uncovering the cause of this rare and curious condition.

How to Give an Insulin Injection

August 29th, 2011

For those newly diagnosed insulin dependent diabetics, or those caring for someone newly diagnosed, WebMD has developed a six-step "Action Set" on giving an insulin injection to your self or to someone else.

The instructional guide, found online in the Diabetes Health Center, starts with basic information on insulin therapy, and then leads into detailed information on preparing an insulin dose and giving an insulin injection. The information links to illustrative slideshows demonstrating the techniques.

>CLICK HERE< to view the Action Set and slideshows on giving an insulin shot on WebMD.

Flying Can Cause Changes in Insulin Pump Performance

August 30th, 2011 is warning insulin dependent diabetes planning to take a plane that changes in cabin air pressure while flying may alter the functioning of insulin pumps. The research arose out of an incident involving a young diabetic traveler using an insulin pump whose blood sugar levels dropped unexpectedly one hour into a flight.

After uncovering reports of similar incidents involving insulin pumps delivering incorrect insulin doses while being used on planes, a team of researchers from John Hunter Children's Hospital in Australia decided to perform some tests.

They placed ten insulin pumps on a commercial flight. When they analyzed them later, they found the pumps delivered 1 to 1.4 extra units of insulin after take-off, and that a small amount of insulin was drawn back into the pumps when descending for a landing.

To read the entire story on, including the researchers' suggestions for diabetics with insulin pumps who plan to travel byplane, >CLICK HERE.<

Home Urine Test Measures Insulin Production in Diabetics

August 31st, 2011

A simple home urine test has been developed which can measure if patients with type 1 and type 2 diabetes are producing their own insulin. The urine test replaces multiple blood tests in hospital and can be sent by mail, as it is stable for up to three days at room temperature. Avoiding blood tests will be a particular advantage for children with diabetes.

The urine test measures if patients are still making their own insulin even if they take insulin injections. Researchers have shown that the test can be used to differentiate Type 1 diabetes from Type 2 diabetes and from rare genetic forms of diabetes.

One woman with a genetic form of diabetes whose urine test revealed that she was still making her own insulin was able to stop taking insulin injections after 14 years of insulin treatment. To read more about this promising home urine test on ScienceDaily, >CLICK HERE.<